Novel Technologies and Approaches Targeting the Immuno-Oncology of Tumours

Takeda Pharmaceutical are launching an open innovation initiative inviting researchers to submit their proposals addressing novel technologies and approaches related to immuno‑oncology of tumours. One‑year projects will be funded up to JPY 10,000,000 or equivalent amount, including indirect costs.

Projects should address one of two areas:

REF#3 Induction of anti‑tumour effects in ‘cold’ tumours insensitive to immune checkpoint inhibitors.

• Clinically relevant models that faithfully recapitulate the microenvironment of ‘cold’ tumours
• Proposals addressing tumour-promoting inflammation and tumour evasion of immune destruction
• Proposals addressing novel mechanisms of genome instability and mutations in tumour (classical DNA damage response will be out of focus)

REF#4 Innovative and differentiated technologies/concepts feeding into the immuno-oncology drug discovery for solid tumours.

• Novel technologies enabling a selective drug delivery to the tumour microenvironment (TME) or tumour-draining lymph nodes (TDLN) via systemic administration (excluding conventional antibody-drug conjugate approaches)
• Novel approaches/models for target identification/validation focusing on the modulation of anti‑tumour immune responses by: (i) cancer-associated fibroblasts, or (ii) B cells/tertiary lymphoid structures (TLS) in the TME
• Multidimensional single-cell studies aiming for the discovery of novel disease mechanisms/drug resistance mechanisms (such as immune checkpoint blockade) in cancer patients

Jurisdictions of Interest

Only submissions from Australia, New Zealand, Singapore, South Korea and Taiwan will be eligible for this campaign.

Submission Information

To view more details on each area of interest seeking proposals for funding, download a proposal template here. For terms and conditions, click here. To submit your proposal, please visit our website at discover.in-part.com, register, and submit your proposal under the appropriate Discover campaign.